Head to Head Comparison: OvaScience (NASDAQ:OVAS) and Ampliphi Biosciences Corp (APHB)
OvaScience (NASDAQ: OVAS) and Ampliphi Biosciences Corp (NYSE:APHB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.
Earnings and Valuation
This table compares OvaScience and Ampliphi Biosciences Corp’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Ampliphi Biosciences Corp||$182,999.00||26.98||-$12.29 million||N/A||N/A|
Ampliphi Biosciences Corp has higher revenue, but lower earnings than OvaScience.
Insider and Institutional Ownership
63.5% of OvaScience shares are held by institutional investors. 12.6% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares OvaScience and Ampliphi Biosciences Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ampliphi Biosciences Corp||-11,193.10%||-159.06%||-80.13%|
This is a summary of recent recommendations and price targets for OvaScience and Ampliphi Biosciences Corp, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ampliphi Biosciences Corp||0||0||1||0||3.00|
OvaScience presently has a consensus target price of $8.00, indicating a potential upside of 463.38%. Ampliphi Biosciences Corp has a consensus target price of $10.00, indicating a potential upside of 1,242.28%. Given Ampliphi Biosciences Corp’s stronger consensus rating and higher possible upside, analysts clearly believe Ampliphi Biosciences Corp is more favorable than OvaScience.
OvaScience beats Ampliphi Biosciences Corp on 6 of the 10 factors compared between the two stocks.
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
About Ampliphi Biosciences Corp
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01.
Receive News & Stock Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related stocks with our FREE daily email newsletter.